p53 Status and Response to Radiotherapy in Rectal Cancer
Author Information
Author(s): Lopez-Crapez E, Bibeau F, Thézenas S, Ychou M, Simony-Lafontaine J, Thirion A, Azria D, Grenier J, Senesse P
Primary Institution: Val d'Aurelle Cancer Institute, Montpellier, France
Hypothesis
The study aims to evaluate the predictive role of p53 status in identifying the response to preoperative radiotherapy in rectal adenocarcinoma.
Conclusion
The study found no correlation between p53 alterations and response to radiotherapy in rectal carcinoma.
Supporting Evidence
- 50% of patients had p53 gene mutations.
- 44.4% of patients had allelic loss.
- 55.7% of patients showed nuclear p53 overexpression.
- 16.7% of patients had detectable p53 antibodies.
- 41.4% of patients were downstaged by pathologic analysis.
- 29.2% of patients were classified as tumour regression grade 1.
- No correlation was found between p53 alterations and response to radiotherapy.
Takeaway
This study looked at how a gene called p53 affects how well rectal cancer patients respond to radiation treatment, and it found that p53 changes don't help predict the treatment's success.
Methodology
The study involved a prospective analysis of 70 rectal cancer patients, assessing p53 status through various methods and evaluating treatment response post-surgery.
Potential Biases
Potential biases may arise from the subjective nature of histopathological evaluations.
Limitations
The study had a small sample size and some patients lacked measurements for all variables, reducing the power of the analysis.
Participant Demographics
The study included 70 patients, with 43 men and 27 women, median age of 65 years.
Statistical Information
P-Value
P<0.0001 for gene mutations correlating with nuclear protein overexpression; P=0.013 for loss of heterozygosity.
Confidence Interval
95% confidence interval (CI), 0.11–0.95
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website